What’s Going On With Tempus AI Stock on Monday?
Key takeaways
- TEM’s recent pullback reflects a re‑pricing of its momentum‑driven rally, with FDA clearance adding a new product but analyst sentiment remaining split.
- TEM shares down 6.78% to $67.76
- TEM’s $1.5 billion deal with Personalis
- BTIG target raised to $80
What happened
Tempus AI Inc (NASDAQ: TEM) shares fell 6.78% to $67.76 on Monday after a roughly 20% rally over the past week. The pullback follows hype around Phase 3 results for Merck’s and Moderna’s intismeran neo‑antigen therapy combined with Keytruda, which spotlighted TEM’s $1.5 billion deal with Personalis Inc. (NASDAQ: PSNL). In addition, TEM received FDA 510(k) clearance for its ECG‑PH AI tool that detects pulmonary hypertension from a standard ECG, adding a new diagnostic product to its portfolio.
Why it matters
The recent surge was largely driven by momentum from the mRNA therapy data, not by TEM’s own earnings or product launches. The FDA clearance expands TEM’s product line, potentially boosting revenue streams, but the market reaction suggests investors are still weighing the company’s valuation and the competitive…
Short-term and longer-term
Short-term. Short‑term traders should monitor TEM’s support around $65 and resistance near $75, as the stock’s momentum score remains high (83.09).
Longer-term. Long‑term investors should assess whether TEM can translate its AI platform into sustainable revenue growth beyond the Personalis deal.